We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+17.63%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.7B
AUM Growth
+$43.5M
Cap. Flow
-$109M
Cap. Flow %
-6.45%
Top 10 Hldgs %
43.98%
Holding
67
New
4
Increased
4
Reduced
33
Closed
4
Avg Time Held
13.3 quarters
Top 10 Avg Time Held
6.2 quarters
Top 20 Avg Time Held
5.4 quarters

Top Buys

Rank Stock Value
1
ORKA icon
Oruka Therapeutics
ORKA
+$14.3M
2
BNTX icon
BioNTech
BNTX
+$14.2M
3
RGNX icon
Regenxbio
RGNX
+$3.94M
4
ATXS icon
Astria Therapeutics
ATXS
+$3.46M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$3.13M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$40.7M
2
FOLD icon
Amicus Therapeutics
FOLD
+$25.6M
3
BPMC icon
Blueprint Medicines
BPMC
+$10.2M
4
KYMR icon
Kymera Therapeutics
KYMR
+$8.21M
5
TRDA icon
Entrada Therapeutics
TRDA
+$7.99M

Sector Composition

Rank Sector Weight
1 Healthcare 97.73%
2 Industrials 2.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
KRYS icon
1
Krystal Biotech
KRYS
$9.56B
$147M 8.69%
810,245
-210,833
-21% -$40.7M
2018 Q4
23 quarters
NRIX icon
2
Nurix Therapeutics
NRIX
$2.6B
$96.2M 5.67%
4,280,981
-142,635
-3% -$3.23M
2020 Q3
16 quarters
FOLD icon
3
DELISTED
Amicus Therapeutics
FOLD
$88.1M 5.19%
8,246,592
-2,348,497
-22% -$25.6M
2013 Q2
45 quarters
IMNM icon
4
Immunome
IMNM
$2.04B
$71.5M 4.21%
4,889,554
– –
2023 Q4
3 quarters
KYMR icon
5
Kymera Therapeutics
KYMR
$8.85B
$65.9M 3.88%
1,393,256
-186,019
-12% -$8.21M
2020 Q3
16 quarters
ZYME icon
6
Zymeworks
ZYME
$1.77B
$64M 3.77%
5,101,911
-109,126
-2% -$1.19M
2020 Q1
18 quarters
STOK icon
7
Stoke Therapeutics
STOK
$1.47B
$57.9M 3.41%
4,713,509
-7,545
-0.2% -$107K
2019 Q2
21 quarters
REPL icon
8
Replimune Group
REPL
$1.1B
$52.4M 3.09%
4,781,183
-780,913
-14% -$7.93M
2018 Q3
24 quarters
BHVN icon
9
Biohaven
BHVN
$1.64B
$51.7M 3.04%
1,034,219
-53,357
-5% -$2.08M
2023 Q3
4 quarters
RGNX icon
10
Regenxbio
RGNX
$457M
$51.3M 3.02%
4,892,902
+323,100
+7% +$3.94M
2017 Q1
30 quarters
IGMS icon
11
DELISTED
IGM Biosciences
IGMS
$50.8M 2.99%
3,072,478
– –
2019 Q3
20 quarters
ADCT icon
12
ADC Therapeutics
ADCT
$189M
$49.4M 2.91%
15,669,217
+400,000
+3% +$1.26M
2020 Q2
17 quarters
COGT icon
13
Cogent Biosciences
COGT
$4.81B
$48.4M 2.85%
4,484,380
-315,593
-7% -$3.07M
2023 Q2
5 quarters
FATE icon
14
Fate Therapeutics
FATE
$229M
$46.1M 2.72%
13,169,057
– –
2015 Q2
37 quarters
LIVN icon
15
LivaNova
LIVN
$4.17B
$46M 2.71%
875,039
-54,467
-6% -$2.7M
2021 Q1
14 quarters
SRRK icon
16
Scholar Rock
SRRK
$4.78B
$42M 2.47%
5,238,837
-214,246
-4% -$1.88M
2018 Q2
25 quarters
NGNE icon
17
Neurogene
NGNE
$435M
$40.5M 2.38%
964,347
-49,316
-5% -$1.91M
2019 Q4
19 quarters
AKRO icon
18
DELISTED
Akero Therapeutics
AKRO
$39.8M 2.35%
1,387,479
-226,994
-14% -$5.92M
2019 Q2
21 quarters
BEAM icon
19
Beam Therapeutics
BEAM
$2.42B
$39.5M 2.33%
1,611,013
-92,048
-5% -$2.38M
2020 Q1
18 quarters
AUGX icon
20
DELISTED
Augmedix, Inc. Common Stock
AUGX
$38.5M 2.27%
16,380,327
– –
2021 Q4
11 quarters
ANNX icon
21
Annexon
ANNX
$709M
$38.1M 2.24%
6,427,462
– –
2020 Q3
16 quarters
CTLT icon
22
DELISTED
CATALENT, INC.
CTLT
$36.1M 2.13%
595,570
– –
2023 Q1
6 quarters
PLRX icon
23
Pliant Therapeutics
PLRX
$57.2M
$35.8M 2.11%
3,197,491
-12,100
-0.4% -$151K
2020 Q2
17 quarters
SLN icon
24
Silence Therapeutics
SLN
$552M
$34.5M 2.03%
1,899,317
-114,979
-6% -$2.14M
2024 Q1
2 quarters
KROS icon
25
Keros Therapeutics
KROS
$219M
$32.1M 1.89%
552,506
– –
2024 Q1
2 quarters
1
2 3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2024 Portfolio in Review

As of Q3 2024, Redmile Group held 67 positions worth $1.7B, up 2.6% from $1.65B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Redmile Group withdrew a net $109M in Q3 2024, closing 4 positions and reducing 33 holdings. Its most notable exit was Blueprint Medicines, an estimated $10.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Industrials.

Against the trend, Redmile Group opened a new position in Oruka Therapeutics worth $10.1M.

  • Redmile Group's largest Q3 2024 buy was Oruka Therapeutics: 411,728 shares worth $10.1M.
  • Redmile Group added most to Regenxbio in Q3 2024, an estimated $3.94M increase.
  • Redmile Group's biggest Q3 2024 reduction was Krystal Biotech, cutting an estimated $40.7M.
  • Redmile Group fully exited Blueprint Medicines in Q3 2024, selling an estimated $10.2M.
  • Redmile Group's ten largest holdings make up 44% of its $1.7B portfolio in Q3 2024.
  • Redmile Group opened 4 new positions and closed 4 in Q3 2024.
  • Redmile Group's portfolio value rose 2.6% quarter-over-quarter to $1.7B.

Based on Redmile Group's 13F filing for Q3 2024, filed 14 Nov 2024.